CLDN6 and neoplasm: For proof-of-concept studies, we engineered the TCAR to target two well-characterized and safe tumor-associated antigens from the Claudin family of tight junction proteins, Claudin 6 (CLDN6) and Claudin 18.2 (CLDN18.2).